Background
Methods
Study design
Laboratory parameters
Medication treatment
CMR protocol and image analysis
CMR follow-up and major adverse clinical events
Statistical analysis
Results
Demographic and laboratory findings
Medication treatment and temporal recommendation
Study population n = 72 | |
---|---|
Therapy recommendation | |
ASA | 59 (81.9%) |
Clopidogrel | 28 (38.8%) |
Prasugrel | 2 (2.8%) |
Ticagrelor | 4 (5.6%) |
OAC | 12 (16.6%) |
LWMH once per day | 1 (1.4%) |
Statin | 47 (65.3%) |
Beta-blocker | 63 (87.5%) |
ACE inhibitor/AT inhibitor | 63 (87.5%) |
Mineralocorticoid receptor antagonist | 31 (43.1%) |
Duration of antithrombotic therapy | |
No recommendation | 41 (56.9%) |
With recommendation: | 29 (40.3%) |
1 month | 4 (5.6%) |
3 months | 8 (11.1%) |
6 months | 6 (8.3%) |
12 months | 11 (15.3%) |
Reason for OAC | |
Atrial fibrillation | 10 (13.8%) |
Heart failure | 1 (1.4%) |
Deep vein thrombosis | 1 (1.4%) |
Study population n = 72 | |
---|---|
No antiplatelet therapy | 9 (4.2%) |
With OAC monotherapy | 6 |
OAC + ASA | 3 (4.2%) |
Without temporal recommendation | |
OAC + Clopidogrel | 1 (1.4%) |
With temporal recommendation for 3 months | |
Monotherapy antiplatelet: | 28 (38.9%) |
ASA | 25 (34.7%) |
Without temporal recommendation | 24 |
With temporal recommendation for 3 months | 1 |
Clopidogrel | 2 (2.8%) |
Without temporal recommendation | 1 |
With temporal recommendation for 6 months | 1 |
Ticagrelor | 1 (1.4%) |
With temporal recommendation for 12 months | 1 |
Dual antiplatelet therapy: | 29 (40.3%) |
ASA + Clopidogrel | 24 (33.3%) |
Without temporal recommendation | 5 |
With temporal recommendation: | 19 |
1 month | 2 |
3 months | 4 |
6 months | 4 |
12 months | 8 |
ASA + Prasugrel | 2 (2.8%) |
Without temporal recommendation | 1 |
With temporal recommendation for 12 months | 1 |
ASA + Ticagrelor | 3 (4.2%) |
Without temporal recommendation | 0 |
With temporal recommendation | 3 |
1 month | 1 |
3 months | 1 |
12 months | 1 |
“Triple” therapy with ASA | 2 (2.8%) |
1 month, Clopidogrel + OAC 6 months, OAC monotherapy | 1 |
1 month, Clopidogrel + OAK 12 months, OAC monotherapy | 1 |
Implementation of prescribed antithrombotic therapy
CMR parameters and CMR follow-up
CMR parameters | |||
---|---|---|---|
CMR I n = 72 | CMR II n = 63 (88%) |
p-value* | |
LV-EF (%) | 49.1 ± 10.1 | 64.1 ± 5.7 | < 0.001 |
LV-EDVI (ml/m2) | 76.2 ± 13.7 | 72.1 ± 13.9 | 0.198 |
T2 Volume (%) | 13.5 ± 11.3 | 0.6 ± 2.4 | < 0.001 |
LGE Volume (%) | 0.0 ± 0.0 | 0.0 ± 0.0 | |
Δ angiogram-CMR (d) | 2 (1–3.5) | ||
Δ CMR I-CMR II (months) | 2.3 (1.3–2.9) |
MACE and Clinical follow-up analysis
Kaplan-Meier estimation | |||
---|---|---|---|
estimated rate (95%-confidence interval) | |||
MACE | 24 months | 36 months | |
Total events | 9 (12%) | 12.5 (6.4–23.5) | 15.3 (8.0–28.0) |
Death | 4 (5.6%) | 4.6 (1.5–13.5) | 7.6 (2.8–20.3) |
Stroke | 3 (4.2%) | 4.9 (1.6–14.7) | 4.9 (1.6–14.7) |
MI/TTS | 2 (2.8%) | 3.5 (0.9–13.6) | 3.5 (0.9–13.6) |
Study population n = 72 | ||||||
---|---|---|---|---|---|---|
MACE | No AT n = 3 | AT n = 28 | Dual AT n = 29 | OAC n = 6 | AT + OAC n = 4 | Triple therapy n = 2 |
No event | 2 (3%) | 25 (35%) | 25 (35%) | 5 (7%) | 4 (6%) | 2 (3%) |
With Event | 1 (1%) | 3 (4%) | 4 (6%) | 1 (1%) | 0 | 0 |
Myocardial infarction | 0 | 1 (1%) | 0 | 0 | 0 | 0 |
Stroke | 0 | 1 (1%) | 1 (1%) | 1 (1%) | 0 | 0 |
Recurrence of TTS | 0 | 0 | 1 (1%) | 0 | 0 | 0 |
Death | 1 (1%) | 1 (1%) | 2 (3%) | 0 | 0 | 0 |